Australia markets closed

Boundless Bio, Inc. (BOLD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.59-0.51 (-5.60%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 191.04M
Enterprise value 72.48M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-39.72%
S&P500 52-week change 326.27%
52-week high 315.24
52-week low 38.53
50-day moving average 311.19
200-day moving average 311.19

Share statistics

Avg vol (3-month) 3220.53k
Avg vol (10-day) 393.13k
Shares outstanding 522.24M
Implied shares outstanding 623.48M
Float 8791.75k
% held by insiders 111.47%
% held by institutions 151.67%
Shares short (30 Apr 2024) 4849.41k
Short ratio (30 Apr 2024) 44.29
Short % of float (30 Apr 2024) 44.95%
Short % of shares outstanding (30 Apr 2024) 43.82%
Shares short (prior month 28 Mar 2024) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-33.13%
Return on equity (ttm)-52.93%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -53.84M
Net income avi to common (ttm)-49.43M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)120.75M
Total cash per share (mrq)96.94
Total debt (mrq)2.19M
Total debt/equity (mrq)1.82%
Current ratio (mrq)13.27
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-46.85M
Levered free cash flow (ttm)-30.95M